Conatus Pharmaceuticals

Conatus Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of novel therapeutics for the treatment of chronic diseases with significant unmet needs. The company’s lead licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver disease. Additionally, Conatus’ internally developed lead compound, CTS-2090, aims to treat patients with chronic conditions, including inflammatory pathways.